The US Food and Drug Administration has approved a new drug for women with ovarian cancer whose disease has recurred despite treatment with platinum-based chemotherapy. The drug, Zejula (niraparib), is a poly ADP-ribose polymerase (PARP) inhibitor. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News
